SLC5A1 and metabolic dysfunction-associated steatohepatitis: Currently, promising therapeutic targets involved in the clinical treatments of IR-related NASH include Glp-1R, Thr-β, sodium-glucose co-transporter 1/2 (Sglt1/2), PPAR, and Fxr.